Image

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Comparing treatments for advanced lung cancer with EGFR mutations.

Recruiting
18 years and older
All
Phase 3
  • Simplified description (AI rewritten)
  • Technical description (Original)
Study Summary

This study is for people with advanced non-small cell lung cancer (NSCLC) that has an *EGFR* mutation. EGFR stands for *epidermal growth factor receptor*, a protein that can help cancer cells grow. In this study, participants have tried EGFR *tyrosine kinase inhibitors* (TKIs), a type of medicine targeting cancer cells, but their cancer has not stopped progressing.

The study compares two treatments: sacituzumab tirumotecan and a combination of pemetrexed and carboplatin. These are chemotherapy drugs that aim to stop cancer cells from growing. Participants will be randomly assigned to one of these treatments and will continue until they need to stop for specific reasons.

The goal is to see if sacituzumab tirumotecan works better at helping people live longer without their cancer getting worse, which is called progression-free survival (PFS), and overall survival (OS).

  • The study length depends on individual response to treatment.
  • Regular check-ups and tests are required.
  • Participants may face chemotherapy side effects.
Print
Study details
    Non-small Cell Lung Cancer (NSCLC)

NCT06305754

Merck Sharp & Dohme LLC

9 March 2025

Contact a study center
Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.